Posts Tagged ‘lung cancer’

Study: asbestos sprayers most at risk occupation for mesothelioma

14 Jun 2017 by Sarah Mahan under Research/Treatment

800px Bauer Elementary ASBESTOS 2 100x100 Study: asbestos sprayers most at risk occupation for mesotheliomaBack when asbestos was popular in construction and manufacturing, most asbestos-related disease cases were linked to occupation. A recent Finnish study has concluded that those whose job it was to apply spray-on asbestos insulation may be at a highest risk of asbestos-related disease, even compared to those who were employed in other types of asbestos work. (more…)


Researchers look to repurpose drugs to treat cancer

17 Feb 2017 by Sarah Mahan under Research/Treatment

587px Researcher looks through microscope 11 100x100 Researchers look to repurpose drugs to treat cancerWhat if the key to improving treatment for mesothelioma, a deadly cancer associated with exposure to asbestos, lies within medicines or a combination of medicines that already exist? Cancer researchers are working on just that.

Studies are testing to see if a generic drug used for more than 40 years to treat parasitic infections may hold the potential to treat an array of cancers, according to National Public Radio. The drug, mebendazole, is one of a host of drugs, including a diabetes drug and a blood pressure drug, that researchers are studying to determine their ability to be repurposed for cancer treatment. (more…)


Biomarker could help determine between mesothelioma and lung cancer

13 Feb 2017 by Sarah Mahan under Research/Treatment

GHS pictogram silhouette1 100x100 Biomarker could help determine between mesothelioma and lung cancer Sarcomatoid mesothelioma—a subtype of the deadly cancer associated with asbestos exposure—is the rarest form of the cancer and the most resistant to treatment. A new study published in Modern Pathology points to a newly discovered biomarker as a key to differentiating between sarcomatoid mesothelioma and lung sarcomatoid carcinoma, a type of lung cancer mesothelioma is often mistaken as, according to Mesothelioma Research News. (more…)


Study: Pleural mesothelioma patients may require unique form of psychological care

6 Dec 2016 by Sarah Mahan under Research/Treatment

lungs 1 002 100x100 Study: Pleural mesothelioma patients may require unique form of psychological careIn our medical system, care is tailored to the ailment. A person with a broken leg doesn’t receive the same treatment as someone who needs his gallbladder removed. However, psychological patient care for those with pleural mesothelioma, a rare, fatal cancer affecting the lining of the lungs, and caused by exposure to asbestos, has historically been modeled to reflect that of patients with other lung cancers. (more…)


Study links Italian cement plants to higher cases of mesothelioma

27 Apr 2015 by Temp Temple under Research/Treatment

cement Stockage de ciments by Oussama zrafi Own work. Licensed under CC BY SA 3.0 via Wikimedia Commons 100x100 Study links Italian cement plants to higher cases of mesotheliomaA number of asbestos cement plants in Italy have been linked to clusters of mesothelioma victims across the country, according to the results of a new study. Those affected by the deadly disease range from former cement plant employees to even women living nearby the plants. Mesothelioma occurs when asbestos fibers, like those used in the Italian cement plants, have been inhaled or ingested. The fatal cancer can form along the lining of the lungs, abdomen, or, in rare cases, the heart. Unfortunately, there is still no known cure for mesothelioma. (more…)


Lawsuit filed by machinist diagnosed with asbestos-related lung cancer

27 Feb 2014 by Temp Temple under Legal, News

Gavel Scales of Justice American flag square 100x100 Lawsuit filed by machinist diagnosed with asbestos related lung cancerAn asbestos exposure complaint was filed Feb. 12, 2014, by a Pennsylvania man who was recently diagnosed with asbestos-related lung cancer. Working as a machinist for numerous companies, Milton M. Schuster, Sr., was allegedly exposed to asbestos from 1954 through 1985 by his former employers’ products, leading to his diagnosis on Dec. 12, 2013, according to the complaint. (more…)


Meso Foundation commends U.K. efforts on mesothelioma, urges U.S. to follow suit

17 Mar 2010 by Wendi Lewis under Legal, News, Organizations, Research/Treatment
straw Meso Foundation commends U.K. efforts on mesothelioma, urges U.S. to follow suit

UK Justice Secretary Jack Straw

Earlier this month, Chris Hahn, executive director of the Mesothelioma Applied Research Foundation (Meso Foundation) expressed his support for the recent announcement from the UK that it plans to not only endorse compensation for mesothelioma victims, but to promote research and treatment. In a news release, Hahn praised the U.K. for its recognition “that society’s obligation and moral responsibility to remedy the tragic legacy of decades of asbestos use requires funding research to develop effective medical treatments.” Then, he asked the all-important question: “Will the United States follow?”

Hahn’s praise and plea followed remarks by the U.K.’s Lord Chancellor and Secretary of State for Justice, Jack Straw, who has been outspoken about the government’s role in caring for workers harmed by asbestos on the job.  Straw issued a statement Feb. 25, 2010, in response to an ongoing debate over the government’s decision on the question of compensation for pleural plaques.

Although pleural plaques, which are small areas of fibrosis in the pleura of the lung caused by asbestos exposure, indicate that a person has been exposed to asbestos, they generally do not cause any significant change in lung function. As a result, the Law Lords on Oct. 17, 2007 determined that people who have pleural plaques, but no other asbestos-caused illness, are not eligible for any compensation for medical treatment or other financial claims. The debate over pleural plaques sparked a national debate about asbestos disease.

Although subsequent research did not provide enough evidence to overturn the Law Lords’ ruling, it has provided significant information about asbestos disease, including mesothelioma and lung cancer. The government also is establishing a number of policies to make it easier for those who are diagnosed with mesothelioma or serious asbestos disease to receive compensation more quickly. Additionally, the research has encouraged the UK government to take a stronger stand on mesothelioma research and treatment.

According to Straw’s statement, “The fact that the UK has one of the highest rates of death from mesothelioma in the world is a legacy of our industrial heritage and the part that asbestos played in it. Just as the UK was a global leader in the asbestos industry, we must now become a global leader in research into asbestos-related disease.”

The government of the UK is calling for the creation of a National Centre for Asbestos-Related Disease, which will be a “collaborative network of funded researchers whose core purpose would be to advance medical research into the prevention, cure and alleviation of asbestos-related disease – primarily mesothelioma,” according to Straw. He said the insurance industry has pledged £3 million toward this research effort.

Benefits of such a concentrated and cooperative research and treatment program would not only benefit mesothelioma patients, but also would significantly reduce the costs of litigation, death and disability benefits, and health care costs, Hahn points out.

“This is exactly what the Mesothelioma Applied Research Foundation has been urging in the United States the past ten years,” Hahn says. “Mesothelioma and other asbestos-related diseases are a fundamental problem of social justice. And a just solution to that problem requires medical research to develop effective treatments to end the suffering and save lives. It is encouraging to see that the U.K. is getting it; we hope the U.S. will catch up soon.”

Read Hahn’s statement.

For more information, visit the Meso Foundation online at www.curemeso.org.


ADAO praises senate for asbestos awareness resolution

5 Mar 2010 by Wendi Lewis under Events, News, Organizations

adao logo ADAO praises senate for asbestos awareness resolutionThis week the Asbestos Disease Awareness Organization (ADAO) praised Senate leaders for a resolution that declares the first week of April 2010 as “National Asbestos Awareness Week.” This is the sixth year in a row that the ADAO has been active in working with Senate leaders to secure a national resolution in recognition of the dangers of asbestos.

The resolution is sponsored by Sen. Max Baucus (D-Mont.). Co-sponsors and key supporters are Sen. Barbara Boxer (D-Calif.), Sen. Richard Durbin (D-Ill.), Sen. Dianne Feinstein (D-Calif.), Sen. Johnny Isakson (R-Ga.), Sen. Patrick Leahy (D-Vt.), Sen. Patty Murray (D-Wash.), Sen. Harry Reid (D-Nev.) and Sen. Jon Tester (D-Mont.).

A news release from the ADAO quotes the organization’s Co-Founder and Executive Director Linda Reinstein as saying, “We are grateful to the U.S. Senate to have the opportunity to help raise the level of public awareness about the prolific dangers of asbestos and further unite doctors, scientists, and public health advocates during National Asbestos Awareness Week for this important effort. During the past six years, ADAO has seen the progress and indeed, this confirms what Americans deserve and want. We know asbestos prevention and education will save lives and dollars.”

The ADAO was founded by asbestos victims and their families in 2004. It seeks to give asbestos victims and concerned citizens a united voice to raise public awareness about the dangers of asbestos exposure. ADAO’s mission includes supporting global advocacy and advancing asbestos awareness, prevention, early detection, treatment, and resources for asbestos-related disease.

Asbestos is a known human carcinogen and exposure can cause asbestos-related diseases, including mesothelioma, lung cancer and asbestosis. According to the ADAO news release, studies estimate that during the next decade 100,000 workers around the world will die of an asbestos-related disease. This equals 30 deaths per day.

The ADAO annually holds a conference in conjunction with National Asbestos Awareness Week. The Sixth Annual International Asbestos Conference is set for April 10, 2010, in Chicago, Ill.

For more information about ADAO or for conference registration, visit ADAO online at www.asbestosdiseaseawareness.org.


Mesothelioma cases on the rise in South Korea

1 Mar 2010 by Wendi Lewis under Events, News

south korea1 100x100 Mesothelioma cases on the rise in South KoreaHealth officials in South Korea are recording significant increases in asbestos-related diseases among the country’s population, including asbestosis, lung cancer and malignant mesothelioma. According to a report by TIME Magazine, the number of mesothelioma diagnoses increased from just 12 in 2001, to 55 new cases in 2007, the most recent year that data is available. It is, “in public health terms, a notable increase,” TIME quotes Paek Dom-yung, an occupational medicine professor at Seoul National University.

While South Korea enjoyed a boom in urban development from the 1960s through the 1980s, it is becoming evident the country’s lax rules on asbestos regulation may have exposed millions of people to health hazards. According to the TIME report, Seoul did not place a full ban on asbestos manufacturing, import and use until last year. It also had no regulations in place for the safe removal of existing asbestos during demolition and remodeling projects.

Now, trade and labor unions in South Korea are calling for the government to take responsibility for workers it knowingly exposed to deadly asbestos, and who are now suffering as a result.

Due to the long latency period between exposure and the development of mesothelioma or other asbestos diseases – which can be as long as 20-50 years – South Korean health officials are bracing for a future epidemic. It is predicted that the incidence of mesothelioma diagnoses in the region will not peak until around 2030.


Alimta developer to be inducted into Chemistry Hall of Fame

1 Jan 2010 by Wendi Lewis under News, People, Research/Treatment

edward taylor 100x100 Alimta developer to be inducted into Chemistry Hall of FamePrinceton University announced Edward Taylor, its A. Barton Hepburn Professor of Organic Chemistry Emeritus, will be inducted into the American Chemical Society (ACS) Division of Medicinal Chemistry Hall of Fame in 2010. Additionally, Taylor has been inducted into the New Jersey Inventors Hall of Fame and was selected to receive the 2010 Alfred Burger Award in Medicinal Chemistry from the ACS. Taylor was instrumental in the development of Alimta, a drug manufactured by Eli Lilly and Co. and approved for the treatment of malignant pleural mesothelioma by the U.S. Food & Drug Administration in 2004.

Taylor was recently honored for his accomplishments at the Celebrate Princeton Invention reception, held Dec. 18. He developed Alimta in partnership with scientists at Eli Lilly and Co.  after spending more than 40 years on the Princeton faculty. However, he began research that would lead to the mesothelioma drug’s development while a graduate student at Cornell University.

According to a Princeton news release, Taylor became fascinated by reports of a compound obtained from spinach and liver that had a unique chemical structure with a nucleus previously only observed in the pigments of butterfly wings. The compound from liver, now known as folic acid, he found was essential for the synthesis of DNA and RNA, and for the growth of cells.  Taylor observed that changes to the structure of folic acid could transform it from a growth-promoting to a growth-inhibiting compound, and dedicated his career to determine how it could be used to kill cancer cells.

Since its approval by the FDA in 2004, the drug has received three additional FDA approvals, most recently in July when it became the first chemotherapy approved for use as a maintenance therapy for patients with locally advanced or metastatic nonsquamous non-small cell lung cancer. Alimta has been successful in improving the quality of life and extending the lifespan of millions of cancer patients in nearly 100 countries around the world.

Taylor has previously been honored with the ACS Heroes of Chemistry Award, the International Society of Heterocyclic Chemistry Senior Award in Heterocyclic Chemistry, and the Research and Development Council of New Jersey’s Thomas Alva Edison Patent Award for Invention.